Nirali N. Shah
#129,141
Most Influential Person Now
American physician-scientist and pediatric hematologist-oncologist
Nirali N. Shah's AcademicInfluence.com Rankings
Nirali N. Shahphilosophy Degrees
Philosophy
#11117
World Rank
#15260
Historical Rank
#2103
USA Rank
Logic
#7908
World Rank
#9839
Historical Rank
#1252
USA Rank
Download Badge
Philosophy
Nirali N. Shah's Degrees
- Bachelors Biomedical Engineering Johns Hopkins University
- Masters Clinical Research University of Pennsylvania
Why Is Nirali N. Shah Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.
Nirali N. Shah's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial (2015) (2318)
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy (2017) (735)
- Mechanisms of resistance to CAR T cell therapy (2019) (499)
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. (2013) (466)
- CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL (2017) (295)
- Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. (2015) (196)
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. (2020) (191)
- CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study (2016) (169)
- Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22 (2018) (159)
- Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (2017) (158)
- Treatment of intraocular retinoblastoma with vincristine and carboplatin. (2003) (152)
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial (2021) (135)
- Secondary solid cancer screening following hematopoietic cell transplantation (2015) (130)
- Characterization of CD22 expression in acute lymphoblastic leukemia (2015) (124)
- Epigenetic Modulation of Homer1a Transcription Regulation in Amygdala and Hippocampus with Pavlovian Fear Conditioning (2012) (112)
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma (2018) (111)
- Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence (2019) (100)
- Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. (2021) (95)
- Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation (2016) (93)
- Immunogenicity of CAR T cells in cancer therapy (2021) (82)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
- The effect of angiotensin‐blocking agents on liver fibrosis in patients with hepatitis C (2009) (78)
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
- Outcome after local recurrence of osteosarcoma (2004) (73)
- More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. (2019) (65)
- Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. (2014) (64)
- A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL) (2011) (59)
- Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias (2016) (53)
- Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency. (2019) (51)
- Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells (2017) (51)
- Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy (2018) (51)
- Updates on CAR T‐cell therapy in B‐cell malignancies (2019) (50)
- Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. (2018) (49)
- Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. (2019) (49)
- Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies (2020) (48)
- Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (2016) (48)
- Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. (2015) (48)
- Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics. (2019) (47)
- Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia (2015) (43)
- Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion (2022) (41)
- Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide. (2017) (41)
- Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL (2021) (40)
- Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells. (2021) (35)
- A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621 (2019) (34)
- Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. (2014) (33)
- Phase I Study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. (2017) (31)
- Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation (2020) (31)
- Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. (2018) (29)
- Food allergies can persist after myeloablative hematopoietic stem cell transplantation in dedicator of cytokinesis 8-deficient patients. (2016) (29)
- Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. (2016) (29)
- The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. (2020) (28)
- Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. (2017) (28)
- Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells (2021) (27)
- Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK8-deficient patients. (2019) (26)
- Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy (2020) (25)
- Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. (2015) (23)
- Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS (2016) (22)
- Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Can Render Patients with ALL Into PCR-Negative Remission and Can be an Effective Bridge to Transplant (HCT) (2018) (22)
- The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. (2021) (20)
- Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis. (2011) (20)
- Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases. (2020) (20)
- Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience (2018) (20)
- Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. (2020) (20)
- Haploidentical related donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for DOCK8 deficiency. (2016) (20)
- Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival (2020) (20)
- Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. (2014) (18)
- Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (2015) (18)
- CD19/22 CAR T-cells in Children and Young Adults with B-ALL: Phase I Results and Development of a Novel Bicistronic CAR. (2022) (17)
- Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design (2021) (17)
- Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor. (2018) (16)
- Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621 (2022) (15)
- Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells (2022) (15)
- Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2013) (15)
- Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia (2020) (14)
- CAR T cells better than BiTEs. (2021) (14)
- A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. (2020) (13)
- Infectious Complications of CAR T-Cell Therapy Across Novel Antigen Targets in the first 30 days. (2021) (13)
- Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. (2017) (13)
- A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies. (2020) (12)
- Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. (2016) (12)
- Results from an international phase 2 study of the anti‐CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B‐lineage acute lymphoblastic leukemia (2020) (11)
- Disease detection methodologies in relapsed B‐cell acute lymphoblastic leukemia: Opportunities for improvement (2020) (11)
- DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation (2017) (11)
- Abstract CT230: Pediatric phase 1 trial of moxetumomab pasudotox: Activity in chemotherapy refractory acute lymphoblastic leukemia (ALL) (2014) (11)
- Donor source and post‐transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency (2021) (10)
- Improving CAR T-cells: The next generation. (2020) (10)
- Early recovery of circulating immature B cells in B‐lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection (2018) (10)
- Immunotherapy for Pediatric Leukemia (2013) (10)
- Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation (2017) (10)
- Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors (2019) (10)
- Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. (2014) (9)
- Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates (2016) (9)
- Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response (2018) (9)
- Cardiac metastasis and hypertrophic osteoarthropathy in recurrent infantile fibrosarcoma (2012) (9)
- Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy (2021) (9)
- Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. (2018) (8)
- Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia (2021) (8)
- Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy (2017) (8)
- Abstract CT051: Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL (2020) (8)
- The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. (2019) (8)
- Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains (2018) (8)
- CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort (2017) (7)
- Anakinra utilization in refractory pediatric CAR T-cell associated toxicities (2022) (7)
- Compound Heterozygous DOCK8 Mutations in a Patient with B Lymphoblastic Leukemia and EBV-Associated Diffuse Large B Cell Lymphoma (2019) (7)
- Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells (2021) (7)
- Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer (2021) (7)
- Psychosocial care for children receiving chimeric antigen receptor (CAR) T‐cell therapy (2020) (7)
- Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation (2022) (7)
- KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy (2021) (7)
- Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL). (2020) (7)
- Tandem Orthotopic Living Donor Liver Transplantation Followed by Same Donor Haploidentical Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency: Tandem Liver and Bone Marrow Transplant in DOCK8 Deficiency. (2019) (7)
- Children as hematopoietic cell donors in research: when is it approvable? (2015) (7)
- Research article Impedance platelet count in severe microcytosis-study of 161 patients (2014) (6)
- The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells (2017) (6)
- Utilization of palliative care consultations in pediatric oncology phase I clinical trials (2019) (6)
- Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis (2020) (6)
- Anti-CD19 resistance can "stem" from progenitors. (2017) (6)
- Abstract LB-146: Phase I CD22 CAR T-cell trial updates (2019) (6)
- Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report (2020) (5)
- Case report: Impact of BITE on CAR‐T cell expansion (2019) (5)
- Efficacy and Kinetics of CAR-T Cell Therapy in Children and Young Adults with Extramedullary Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) (2018) (5)
- Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells (2021) (5)
- Infectious Complications Associated with CAR T-Cell Therapy (2019) (5)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy (2021) (5)
- Haploidentical Transplantation for DOCK8 Deficiency (2015) (5)
- Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. (2018) (5)
- Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: Diagnostic and therapeutic challenges (2012) (5)
- A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy (2016) (5)
- Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia. (2021) (5)
- The one-two punch (of CAR T cells). (2020) (4)
- GATA2 Deficiency: Early Identification for Improved Clinical Outcomes. (2019) (4)
- GVL for ATL? (2013) (4)
- Test Dose Pharmacokinetics in Pediatric Patients Receiving Once‐Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach? (2018) (4)
- Antibody Based Therapies in Acute Leukemia. (2017) (4)
- Cryptosporidium infection in Dedicator of Cytokinesis 8 (DOCK 8) Deficiency. (2020) (4)
- Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation (2021) (4)
- A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox (HA22, CAT-8015): Activity in Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplantation (SCT) (2012) (4)
- Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer (2012) (4)
- Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument (2019) (4)
- Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia (2014) (3)
- CLONAL HEMATOPOIESIS IN RELATED ALLOGENEIC TRANSPLANT DONORS: IMPLICATIONS FOR SCREENING AND MANAGEMENT. (2020) (3)
- Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (2019) (3)
- Pilot Study of Educational Interventions for Pediatric Hematopoietic Stem Cell Sibling Donors to Increase Knowledge of Donation and Transplantation Procedures. (2019) (3)
- Immunotherapy Associated Neurotoxicity in Pediatric Oncology (2022) (3)
- Women in immunology: 2020 and beyond (2020) (3)
- The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes (2022) (3)
- Hematopoietic Cell Transplantation and Outcomes Related to Human Papillomavirus Disease in GATA2 Deficiency. (2021) (3)
- Factors Impacting Overall and Event Free Survival Following Post-CAR T-cell Consolidative Hematopoietic Stem Cell Transplant. (2021) (3)
- Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group (2016) (3)
- Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review (2022) (3)
- Using single-cell analysis to predict CAR T cell outcomes (2020) (2)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Deficiency (2015) (2)
- Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions (2022) (2)
- Expanded access trial of tocilizumab in COVID19+hospitalized cancer patients (2020) (2)
- Surviving the storm: critical care outcomes of chimeric antigen receptor T-cell therapy. (2021) (2)
- Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions (2022) (2)
- Addendum to: Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency Using Post-Transplantation Cyclophosphamide. (2019) (2)
- Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel (2022) (2)
- Emerging frontiers in immuno- and gene therapy for cancer. (2022) (2)
- MUTATIONS IN THE TYROSINE-PROTEIN KINASE LYN CAUSE AN EARLY-ONSET NEUTROPHILIC VASCULITIS SYNDROME (2017) (2)
- Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Receptor T-Cell Viability and Fold Expansion, Reducing Total Culture Duration (2018) (2)
- Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. (2020) (2)
- Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia (2020) (2)
- Abstract 4231: Factors predictive of CAR T cell associated hemophagocytic lymphohistiocytosis (HLH) (2020) (1)
- A mass in the anal canal found to be poorly differentiated small-cell neuroendocrine carcinoma (2020) (1)
- Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells (2022) (1)
- Fertility and CAR T-cells: Current practice and future directions. (2022) (1)
- Invasive fusariosis masquerading as extramedullary disease in rapidly progressive acute lymphoblastic leukemia (2019) (1)
- Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK 8-deficient patients (2019) (1)
- Study of coagulation profile in malaria (2020) (1)
- Neurotoxicity Following CD19/CD28ζ CAR T-Cells in Children and Young Adults with B-Cell Malignancies. (2022) (1)
- Porphyria cutanea tarda. (2007) (1)
- CAR T-cell therapy for indolent lymphoma: a new treatment paradigm? (2021) (1)
- Transplant Outcomes for Children with T-Cell Acute Lymphoblastic Leukemia in Second Remission: A Report of the CIBMTR® (2015) (1)
- Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy (2022) (1)
- A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies and Post-Transplant Relapse (2011) (1)
- Incidence of Epstein-Barr Virus (EBV) Detection in the Blood, Pre-Emptive Therapy, and EBV-Posttransplantation Lymphoproliferative Disorder (EBV-PTLD) after Allogeneic Hematopoietic Cell Transplantation (HCT) across a Broad Range of HCT Approaches and All Graft Sources (2019) (1)
- Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases (2022) (1)
- Mapping the Landscape of Advance Care Planning in Adolescents and Young Adults Receiving Allogeneic Hematopoietic Stem Cell Transplantation: a 5-Year Retrospective Review (2021) (1)
- Abstract LB-138: Autologous-collected anti-cd19 chimeric antigen receptor (CAR) T cells for acute lymphocytic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL) in children who have previously undergone allogeneic hematopoietic stem cell transplantation (HSCT). (2013) (1)
- A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell (DC) Vaccination and Donor Lymphocyte Infusion (DLI) for WT1-Expressing Hematologic Malignancies and Post-Transplant Relapse (2012) (1)
- Antenatal Screening for Group B Streptococcus in the Setting of Preterm Premature Rupture of Membranes: Empiric versus Culture-based Prophylaxis (2017) (1)
- Autologous-collected anti-CD19 chimeric antigen receptor T cells (19CARTs) for pediatric acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL): Clinical activity and cytokine release without graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). (2013) (1)
- Resolution of Pulmonary Arterial Hypertension (PAH) in a Patient with GATA-2 Deficiency Following Bone Marrow Transplant (BMT) (2019) (1)
- Research involving pediatric stem cell donors: A way forward (2016) (1)
- Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome (2017) (1)
- Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR T-Cell Therapy (2020) (1)
- Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre‐transplant minimal residual disease reduction (2020) (1)
- Monoclonal Antibody-Based Treatment and Other New Agents for B-Lineage Acute Lymphoblastic Leukemia (2022) (1)
- Constitutively active Lyn kinase causes a cutaneous small vessel vasculitis and liver fibrosis syndrome (2022) (1)
- Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products (2022) (1)
- How We Use Risk Factors for Success or Failure of CD19 CAR T-cells to Guide Management of Children/AYA with B-cell ALL. (2022) (1)
- Abstract PO-092: Expanded access trial of tocilizumab in COVID19+ hospitalized cancer patients (2020) (1)
- Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation (2012) (1)
- How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy. (2023) (0)
- Current Status and Future Directions of Gene-Based Therapy for Pediatric Blood Diseases. (2022) (0)
- Cell-Based Therapies: A New Frontier of Personalized Medicine (2018) (0)
- Faculty Opinions recommendation of Monitoring PD-1 phosphorylation to evaluate PD-1 signaling during anti-tumor immune responses. (2021) (0)
- A SNIPpet of safety: a Goldilocks approach in CAR-T therapy (2022) (0)
- Successful Allogeneic Hematopoietic Cell Transplantation (HCT) with Low Toxicity and Gvhd in a Heterogeneous Cohort of Primary Immunodeficiency (PID) Patients (2019) (0)
- Limited Usefulness of Bronchoalveolar Lavage (BAL) in the Diagnosis of Pulmonary Infiltrates after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) (2015) (0)
- Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK8-deficient patients inactivating mutations in DOCK8 cause a combined immunodeficiency characterized by severe pathogen infections, (2019) (0)
- Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with GATA 2 Deficiency: Influence of Donor Stem Cell Source and Post-Transplantation Cyclophosphamide (2020) (0)
- Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia. (2022) (0)
- CNS Disease at Diagnosis May Predict Relapse of Hematologic Malignancies in Pediatric Patients After Allogeneic Hematopoietic Cell Transplantation (AlloHCT) (2013) (0)
- Ex Vivo T Cell Depleted HLA-Matched PBSCT with Post-Transplant Activated Donor-Derived NK Cell Infusions for High-Risk Acute Lymphoblastic Leukemia (2015) (0)
- Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (2021) (0)
- Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial (2022) (0)
- Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies. (2018) (0)
- Advances and Challenges in Pediatric and Childhood Cancers. (2020) (0)
- The CD19neg needle in the haystack. (2022) (0)
- Early Experience with a Radiation- and Serotherapy-Free Reduced Intensity Conditioning Platform for Allogeneic Bone Marrow Transplantation (alloBMT) in Primary Immunodeficiency (PID) (2018) (0)
- Pain, Symptoms, AEs, and Recovery after Second Unrelated Donor Collection of Marrow/Peripheral Blood Stem Cells Are Similar to Those of the First Donation (2016) (0)
- Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT) (2020) (0)
- Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). (2023) (0)
- Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy (2016) (0)
- P287 The big masquerade: atopy as the presenting symptom of DOCK8 deficiency (2017) (0)
- CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia (2022) (0)
- Abstract A46: Charting the synthetic lethality landscape in pediatric cancer to advance whole-exome precision-based treatments (2020) (0)
- Peripheral Blood Stem Cell Collection in One Day Is Preferable to Two Days in Unrelated Donors (2019) (0)
- CAR T-cells effective for post-CART relapse: A new treatment paradigm. (2022) (0)
- Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India (2022) (0)
- CD70 CAR T cells in AML: Form follows function (2022) (0)
- Acute lymphoblastic leukemia Inotuzumab ozogamicin in pediatric patients with relapsed / refractory acute lymphoblastic leukemia (2019) (0)
- Nomenclature for Cellular and Genetic therapies: A Need for Standardization. (2022) (0)
- Results of point-of-care manufacturing of bispecific chimeric antigen receptor (CAR) LV20.19 CAR-TCELLS in a phase i study for relapsed/refractory (R/R), non-hodgkin lymphoma (NHL) (2019) (0)
- Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK8 2 (2019) (0)
- Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation (2012) (0)
- Ethical Considerations in the Second Decade of Pediatric Phase I CAR T-Cell Trials (2023) (0)
- Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases (2022) (0)
- Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy (2022) (0)
- Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of Childhood ALL by FC and RQ-PCR: A Retrospective Assessment on Behalf of the Pdwp of the Ebmt, the Cog, the Pbmtc, the I-Bfm and the Westhafen-Intercontinental-Group (2017) (0)
- 350 Harnessing arginine metabolism to overcome hyperthermia-induced metabolic dysfunction of CAR T-cells (2022) (0)
- Abstract 3356: Comparative plasma and cerebrospinal (CSF) pharmacokinetics (PK) of vincristine sulfate standard preparation (VCR) and vincristine sulfate liposomes injection (VSLI) in a non-human primate (NHP) model. (2013) (0)
- Prevalence of palliative care consultations in phase I pediatric oncology trials. (2018) (0)
- Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency (2022) (0)
- Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis (2020) (0)
- Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition (2022) (0)
- Evaluating the Prognostic Utility of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) in Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL) Prior to CAR T-Cell Therapy (2023) (0)
- Abstract 1440: Evolution of CD19 expression in pediatric B-cell malignancies in the era of targeted therapy (2019) (0)
- Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse (2022) (0)
- Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells (2017) (0)
- List of Contributors (2020) (0)
- Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. (2021) (0)
- Gene-Based Therapies for Pediatric Blood Diseases (2022) (0)
- Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial (2021) (0)
- CD19 CAR T cells for infants and young children. (2022) (0)
- Impact of Autologous Blood Transfusion after Bone Marrow Harvest on Donor Health and Outcome (2019) (0)
- Leukemias and Lymphomas (2014) (0)
- Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation (AlloHCT) (2013) (0)
- Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations (2019) (0)
- Skip lesions in perianal mucinous adenocarcinoma (2020) (0)
- CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia (2021) (0)
- Treatment o f I ntraocular R etinoblastoma W ith V incristine and C arboplatin (2003) (0)
- Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy (2022) (0)
- Efficacy of Second CAR-T (CART2) Infusion Limited by Poor CART Expansion (2022) (0)
- POINT-COUNTERPOINT POINT CAR T cells better than BiTEs (2021) (0)
- CAR T-Cells for Cure in Pediatric B-ALL. (2023) (0)
- Genome-Wide profiling of viral vector integration in clinical CAR T products using comprehensive methodologies (2020) (0)
- TOC (2020) (0)
- Prognostic Value of IPSS-R Score, Cytogenetic Aberrations, and Cytopenias on Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Myelodysplastic Syndrome in GATA2 Deficiency (2018) (0)
- Pediatric Reduced Intensity Hematopoietic Progenitor Cell Transplantation (HPCT) May Confer Lower Risk of Second Malignant Neoplasms (SMNs) (2012) (0)
- Lymphoma: Burkitt and lymphoblastic lymphoma: clinical therapy and outcome (2013) (0)
- Reporting of Racial and Ethnic Minority Representation in Early Phase Pediatric Oncology Clinical Trials. (2022) (0)
- Histopathological Study of Ovarian Cystic Lesions at a Tertiary Care Hospital in India (2019) (0)
- Disease Detection Methodologies in Acute Lymphoblastic Leukemia (ALL): Opportunities for Improvement (2019) (0)
- Authors' response (2009) (0)
- Patatin-Like Phospholipase Domain-Containing Protein 3(PNPLA3) Gene Polymorphism has a Significantly Stronger Association in Diabetics with Advanced Liver Disease as Compared to Diabetics without Liver Disease (2017) (0)
- Comparative Study of Different Haemoglobin Estimation Methods (2021) (0)
- Synapse disruption in AD brain: Evidence for early pathological clustering of the group I metabotropic glutamate receptor 5 (2011) (0)
- Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) Gene Polymorphism Has a Significantly Stronger Association in Diabetics With Advanced Liver Disease as Compared to Diabetics Without Liver Disease (2017) (0)
This paper list is powered by the following services:
Other Resources About Nirali N. Shah
What Schools Are Affiliated With Nirali N. Shah?
Nirali N. Shah is affiliated with the following schools:
